✦ LIBER ✦

Phase I study of MN-001, an oral anti-inflammatory agent for the treatment of asthma

✍ Scribed by Locke, K.W.

Book ID: 119275552
Publisher: Elsevier Science
Year: 2005
Tongue: English
Weight: 30 KB
Volume: 115
Category: Article
ISSN: 1097-6825
DOI: 10.1016/j.jaci.2004.12.616

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Comparison of roflumilast, an oral anti-

Comparison of roflumilast, an oral anti-inflammatory, with beclomethasone dipropionate in the treatment of persistent asthma

✍ J. Bousquet; M. Aubier; J. Sastre; J. L. Izquierdo; L. M. Adler; P. Hofbauer; K. 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 460 KB

A pilot study of zafirlukast as an anti-

A pilot study of zafirlukast as an anti-inflammatory agent in the treatment of adults with cystic fibrosis

✍ S.P. Conway; C. Etherington; D.G. Peckham; A. Whitehead 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 108 KB

Evaluation of the Antimicrobial, Antioxi

Evaluation of the Antimicrobial, Antioxidant, and Anti-Inflammatory Activities of Hydroxychavicol for Its Potential Use as an Oral Care Agent

✍ Sharma, S.; Khan, I. A.; Ali, I.; Ali, F.; Kumar, M.; Kumar, A.; Johri, R. K.; A 📂 Article 📅 2008 🏛 American Society for Microbiology 🌐 English ⚖ 428 KB

Preliminary observations of oral nicotin

Preliminary observations of oral nicotine therapy for inflammatory bowel disease: An open-label phase I-II study of tolerance

✍ John Robert Ingram; John Rhodes; Brian K Evans; Dr. Gareth A. O. Thomas 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 200 KB

## Background: Transdermal nicotine provides benefit in active ulcerative colitis but is often associated with adverse events (aes). an oral formulation has been developed to minimize aes. this study was undertaken to make initial observations on the safety and tolerance of oral nicotine therapy in

Fingolimod (FTY720) oral for the treatme

Fingolimod (FTY720) oral for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (CIDP): Study design of the phase 3 FORCIDP trial

✍ Hughes, R.; Dalakas, M.; Latov, N.; Léger, J.-M.; Merkies, I.; Nobile-Orazio, E. 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 73 KB

Orally administered, colon-specific muco

Orally administered, colon-specific mucoadhesive azopolymer particles for the treatment of inflammatory bowel disease: An in vivo study

✍ Marta Roldo; Eugen Barbu; James F. Brown; David W. Laight; John D. Smart; John T 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 394 KB

## Abstract Radiolabeled congeners of a series of azopolymers have been synthesized and characterized. The __in vivo__ (rat) gastrointestinal transit profile of millimeter‐sized particles of these azopolymers has been determined and used to facilitate the selection of a candidate material for thera